In this episode of What's up Wednesday, obesity medicine specialist Karli Burridge discusses the outcomes of the recently published study: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial by Timothy Garvey et al., published in Nature Medicine October 10, 2022.The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (behavioral intervention) for long-term treatment of adults with obesity, or preobesity with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104.Listen in to hear the outcomes of the study and how you can incorporate this latest scienc einto your clinical practice!Find the study HERESupport the Treat and Reduce Obesity Act HERESupport the showThe Gaining Health Podcast will release a new episode monthly, every second or third Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer a Roadmap to starting an obesity program or practice, pre-recorded Master Classes, digital resources including patient education materials and office forms, and much more! Check out our resources on our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

Ver todos los episodios